NIGP 26910: Antineoplastic Agents

NIGP 26910 Antineoplastic Agents, an Item code, covers procurement of cancer chemotherapy drugs and related therapeutic agents by state and local health agencies, primarily through pharmacy benefit programs and health plans. State and local governments buy these medications to support employee health benefits, Medicaid populations, correctional health services, and public hospital systems. The issuing bodies for this code include state health and human services departments, state employee benefits programs, county health departments, and municipal hospital systems that maintain formularies and negotiate pricing with pharmaceutical manufacturers, wholesalers, group purchasing organizations, and pharmacy benefit managers.

Texas Health and Human Services Commission posted Request for Information RFI No. HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription fulfillment under a Therapeutic Pharmacy Initiative (TPI) program. The RFI solicits responses from vendors with experience contracting directly with self-insured employers and government health plans without intermediary pharmacy benefit managers or group purchasing organizations, and the state intends to use vendor responses to inform a subsequent formal Request for Proposal with established financial and implementation parameters. The RFI does not specify budget allocation, award value, or set-aside designations at this exploratory phase.